Highly effective targeted therapies are available to treat noncommunicable chronic inflammatory skin diseases. In contrast, the exact diagnosis of noncommunicable chronic inflammatory skin diseases is complicated by its complex pathogenesis and clinical and histological overlap. Particularly, the differential diagnosis of psoriasis and eczema can be challenging in some cases, and molecular diagnostic tools need to be developed to support a gold standard diagnosis. The aim of this work was to develop a real-time PCR-based molecular classifier to distinguish psoriasis from eczema in formalin-fixed and paraffin-embedded-fixed skin samples and to evaluate the use of minimally invasive microbiopsies and tape strips for molecular diagnosis. In this study, we present a formalin-fixed and paraffin-embedded-based molecular classifier that determines the probability for psoriasis with a sensitivity/specificity of 92%/100%, respectively, and an area under the curve of 0.97, delivering comparable results to our previous published RNAprotect-based molecular classifier. The psoriasis probability, as well as levels of NOS2 expression, positively correlated with the disease hallmarks of psoriasis and negatively with eczema hallmarks. Furthermore, minimally invasive tape strips and microbiopsies were effectively used to differentiate psoriasis from eczema. In summary, the molecular classifier offers broad usage in pathology laboratories as well as outpatient settings and can support the differential diagnosis of noncommunicable chronic inflammatory skin diseases on a molecular level using formalin-fixed and paraffin-embedded tissue, microbiopsies, and tape strips.
4 August 2023 in Journal of the European Academy of Dermatology and Venereology
Background: Histopathological differentiation of early mycosis fungoides (MF) from benign chronic inflammatory dermatoses remains difficult and often impossible, despite the inclusion of all available diagnostic parameters.Objective: To identify the most impactful histological criteria for a predictive diagnostic model to discriminate MF from atopic dermatitis (AD).Methods: In this multicentre study, two cohorts of patients with either unequivocal AD or MF were evaluated by two independent dermatopathologists. Based on 32 histological attributes, a hypothesis‐free prediction model was developed and validated on an independent patient's cohort.Results: A reduced set of two histological features (presence of atypical lymphocytes in either epidermis or dermis) was trained. In an independent validation cohort, this model showed high predictive power (95% sensitivity and 100% specificity) to differentiate MF from AD and robustness against inter‐individual investigator differences.Limitations.: The study investigated a limited number of cases and the classifier is based on subjectively evaluated histological criteria.Conclusion: Aiming at distinguishing early MF from AD, the proposed binary classifier performed well in an independent cohort and across observers. Combining this histological classifier with immunohistochemical and/or molecular techniques (such as clonality analysis or molecular classifiers) could further promote differentiation of early MF and AD.
Mycosis fungoides (MF) is a rare cutaneous T cell lymphoma that, in its early stages, can closely mimic eczema and psoriasis in both clinical appearance and histopathologic features, leading to frequent misdiagnosis, inappropriate treatment, and delayed care. Reliable adjunctive biomarkers are lacking, underscoring the need for improved diagnostic strategies. We developed a biomarker discovery framework based on bulk RNA sequencing of skin biopsies (19 MF, 112 psoriasis, 105 eczema), which identified seven candidate diagnostic genes. RT-PCR analysis in FFPE tissue specimens from 65 MF and 101 eczema/psoriasis samples verified LCK and HOMER1 as robust discriminator genes. A logistic regression model based on LCK and HOMER1 gene expression differentiated MF from psoriasis and eczema with 91% sensitivity and 94% specificity. Independent validation on 7 additional international cohorts (MF n=58, eczema/psoriasis n=55) confirmed robust performance. Spatial and single-cell transcriptomic analyses revealed biological underpinnings of classifier accuracy: LCK was enriched in malignant and specific T cell subsets in MF, whereas HOMER1 was confined to keratinocytes in eczema and psoriasis but nearly absent in MF. Case studies demonstrated that the classifier identified MF in routine biopsies earlier than histopathology. This molecular diagnostic approach enables earlier and more reliable distinction of MF from common inflammatory dermatoses, offering a clinically applicable tool to reduce diagnostic uncertainty, accelerate appropriate treatment, and might improve patient outcomes. One Sentence Summary: A two-gene classifier reliably distinguishes mycosis fungoides from eczema and psoriasis, enabling early and accurate diagnosis.
1 October 2017 in Journal of Investigative Dermatology